Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17038
Country/Region: South Africa
Year: 2016
Main Partner: University of the Witwatersrand
Main Partner Program: Maternal, Adolscent and Child Health (MatCH)
Organizational Type: Implementing Agency
Funding Agency: USAID
Total Funding: $11,510,428 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,044,655
Care: TB/HIV (HVTB) $1,408,474
Care: Pediatric Care and Support (PDCS) $257,431
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $514,861
Treatment: Adult Treatment (HTXS) $7,027,576
Treatment: Pediatric Treatment (PDTX) $257,431
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: 10-14 Female 2017 50
GEND_GBV Age/Sex: 15-19 Female 2017 170
GEND_GBV Age/Sex: 20-24 Female 2017 185
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 405
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 405
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 405
GEND_GBV Number of people receiving post-GBV care 2017 810
GEND_GBV Sum of Age/Sex Disaggregates 2017 50
HTS_TST Age/sex: <1 2017 7,002
HTS_TST Age/sex: <1 2017 6,690
HTS_TST Age/sex: 1-9 2017 1,750
HTS_TST Age/sex: 1-9 2017 1,671
HTS_TST Age/sex: 10-14 Female 2017 4,387
HTS_TST Age/sex: 10-14 Female 2017 4,573
HTS_TST Age/sex: 10-14 Male 2017 4,385
HTS_TST Age/sex: 10-14 Male 2017 4,183
HTS_TST Age/sex: 15-19 Female 2017 16,666
HTS_TST Age/sex: 15-19 Female 2017 18,586
HTS_TST Age/sex: 15-19 Male 2017 10,794
HTS_TST Age/sex: 15-19 Male 2017 10,320
HTS_TST Age/sex: 20-24 Female 2017 49,843
HTS_TST Age/sex: 20-24 Female 2017 58,390
HTS_TST Age/sex: 20-24 Male 2017 32,386
HTS_TST Age/sex: 20-24 Male 2017 38,945
HTS_TST Age/sex: 25-49 Female 2017 99,763
HTS_TST Age/sex: 25-49 Female 2017 95,377
HTS_TST Age/sex: 25-49 Male 2017 64,763
HTS_TST Age/sex: 25-49 Male 2017 85,887
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 8,764
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 8,364
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 8,752
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 8,364
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 166,064
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 158,953
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 108,160
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 103,179
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 291,739
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 324,622
HTS_TST Service Delivery Point (Community): Other 2017 45,762
HTS_TST Service Delivery Point (Facility): PMTCT 2017 56,380
HTS_TST Service Delivery Point (Facility): PMTCT 2017 57,119
HTS_TST Service Delivery Point (Facility): VCT 2017 235,359
HTS_TST Service Delivery Point (Facility): VCT 2017 221,741
HTS_TST Sum of Age/Sex disaggregates 2017 282,987
HTS_TST Sum of Age/Sex disaggregates 2017 316,261
HTS_TST Sum of Aggregated Age/Sex <15 2017 17,516
HTS_TST Sum of Aggregated Age/Sex <15 2017 16,728
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 274,224
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 262,132
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 291,740
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 278,860
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 783
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 788
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 784
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 750
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 2,843
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 2,987
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 1,935
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 1,852
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 10,957
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 11,529
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 5,823
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 6,369
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 17,645
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 16,776
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 11,631
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 13,536
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 14
HTS_TST_POS Test Result by Age: Positive: <1 2017 138
HTS_TST_POS Test Result by Age: Positive: <1 2017 133
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 348
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 331
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 467
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 517
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 456
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 515
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 31,375
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 30,041
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 20,344
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 19,408
PMTCT_ART New on ART 2017 6,994
PMTCT_ART New on ART 2017 4,916
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 36,490
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 24,168
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 7,106
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 4,893
PMTCT_EID Sum of Infant Age disaggregates 2017 7,106
PMTCT_EID Sum of Infant Age disaggregates 2017 4,893
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 3,559
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 2,330
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 14,298
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 9,325
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 18,088
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 11,661
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 361
PMTCT_STAT By: Known positives at entry 2017 11,786
PMTCT_STAT By: Known positives at entry 2017 7,805
PMTCT_STAT Number of new ANC and L&D clients 2017 36,631
PMTCT_STAT Number of new ANC and L&D clients 2017 25,422
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 36,490
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 24,168
PMTCT_STAT Required only for DREAMS countries - By known positives: 15-19 2017 1,175
PMTCT_STAT Required only for DREAMS countries - By known positives: 20-24 2017 4,682
PMTCT_STAT Required only for DREAMS countries - By known positives: 25-49 2017 5,870
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 754
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 3,012
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 3,764
PMTCT_STAT Sum of Positives Status disaggregates 2017 11,786
PMTCT_STAT Sum of Positives Status disaggregates 2017 7,805
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 2,456
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 15-19 2017 3,642
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 20-24 2017 14,611
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 9,823
PMTCT_STAT_den Required only for DREAMS countries - Denominator: 25-49 2017 18,228
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 12,288
PP_PREV Aggregated Age/sex: <15 Female 2017 1,686
PP_PREV Aggregated Age/sex: 15+ Female 2017 46,812
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 48,498
PP_PREV Total number of people in the target population 2017 1,203,346
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 199
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 188
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,741
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,619
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 199
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 188
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,434
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,350
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 7,297
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 7,039
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 6,573
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 6,345
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 6,898
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 6,898
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 131,045
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 126,427
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 85,066
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 82,063
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 6,653
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 6,653
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 229,907
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 221,796
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 368
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 354
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 7,012
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6,697
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 368
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 354
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,549
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,348
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 12,297
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 11,753
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 12,909
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 12,342
TX_CURR Age/Sex: <1 2017 1,294
TX_CURR Age/Sex: <1 2017 1,299
TX_CURR Age/Sex: <1-9 2017 2,596
TX_CURR Age/Sex: 1-9 2017 2,598
TX_CURR Age/Sex: 10-14 Female 2017 4,535
TX_CURR Age/Sex: 10-14 Female 2017 4,543
TX_CURR Age/Sex: 10-14 Male 2017 4,519
TX_CURR Age/Sex: 10-14 Male 2017 4,543
TX_CURR Age/Sex: 15-19 Female 2017 12,266
TX_CURR Age/Sex: 15-19 Female 2017 12,320
TX_CURR Age/Sex: 15-19 Male 2017 7,977
TX_CURR Age/Sex: 15-19 Male 2017 8,010
TX_CURR Age/Sex: 20-24 Female 2017 36,784
TX_CURR Age/Sex: 20-24 Female 2017 36,994
TX_CURR Age/Sex: 20-24 Male 2017 23,923
TX_CURR Age/Sex: 20-24 Male 2017 24,020
TX_CURR Age/Sex: 25-49 Female 2017 61,494
TX_CURR Age/Sex: 25-49 Female 2017 61,671
TX_CURR Age/Sex: 25-49 Male 2017 39,891
TX_CURR Age/Sex: 25-49 Male 2017 40,038
TX_CURR Age/Sex: 50+ Female 2017 12,295
TX_CURR Age/Sex: 50+ Female 2017 12,334
TX_CURR Age/Sex: 50+ Male 2017 7,977
TX_CURR Age/Sex: 50+ Male 2017 8,010
TX_CURR Aggregated Age/Sex: <15 Female 2017 85
TX_CURR Aggregated Age/Sex: <15 Male 2017 85
TX_CURR Aggregated Age/Sex: 15+ Female 2017 1,610
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,045
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 215,522
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 216,380
TX_CURR Sum of age/sex disaggregates 2017 20,330
TX_CURR Sum of Age/Sex disaggregations 2017 20,243
TX_CURR Sum of Aggregated Age/Sex <15 2017 170
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 2,655
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 2,825
TX_NEW Aggregated Grouping by Age: <1 2017 370
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 5
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 4
TX_NEW By Age/Sex: <1 2017 375
TX_NEW By Age/Sex: 1-9 2017 746
TX_NEW By Age/Sex: 1-9 2017 742
TX_NEW By Age/Sex: 10-14 Female 2017 1,307
TX_NEW By Age/Sex: 10-14 Female 2017 1,313
TX_NEW By Age/Sex: 10-14 Male 2017 1,303
TX_NEW By Age/Sex: 10-14 Male 2017 1,289
TX_NEW By Age/Sex: 15-19 Female 2017 3,573
TX_NEW By Age/Sex: 15-19 Female 2017 3,536
TX_NEW By Age/Sex: 15-19 Male 2017 2,302
TX_NEW By Age/Sex: 15-19 Male 2017 2,294
TX_NEW By Age/Sex: 20-24 Female 2017 10,844
TX_NEW By Age/Sex: 20-24 Female 2017 10,625
TX_NEW By Age/Sex: 20-24 Male 2017 6,900
TX_NEW By Age/Sex: 20-24 Male 2017 6,875
TX_NEW By Age/Sex: 25-49 Female 2017 18,022
TX_NEW By Age/Sex: 25-49 Female 2017 17,718
TX_NEW By Age/Sex: 25-49 Male 2017 11,505
TX_NEW By Age/Sex: 25-49 Male 2017 11,471
TX_NEW By Age/Sex: 50+ Female 2017 3,603
TX_NEW By Age/Sex: 50+ Female 2017 3,545
TX_NEW By Age/Sex: 50+ Male 2017 2,301
TX_NEW By Age/Sex: 50+ Male 2017 2,298
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 62,163
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 61,920
TX_NEW Sum of Age/Sex disaggregates 2017 61,582
TX_NEW Sum of Age/Sex disaggregates 2017 61,042
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 9
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 200,297
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 200,778
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 180,267
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 180,700
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 5,404
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 5,421
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 5,404
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 5,421
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 102,755
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 103,000
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 66,704
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 66,858
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 733
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 734
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,475
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,467
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,584
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,571
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,584
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,571
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,998
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,972
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,548
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,528
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 20,987
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 20,920
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13,621
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13,580
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 34,926
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 34,846
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22,720
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22,634
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,998
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,972
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,548
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,528
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 22
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 421
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 274
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 123,461
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 122,323
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 131,339
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 130,131
Cross Cutting Budget Categories and Known Amounts Total: $572,903
Human Resources for Health $35,000
Food and Nutrition: Policy, Tools, and Service Delivery $37,421
Motor Vehicles: Leased $360,000
Gender: Gender Based Violence (GBV) $30,000
GBV Prevention
Capacity building
Monitoring and Evaluation
Post GBV Care
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $49,165
Changing harmful gender norms and promoting positive gender norms
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Key Populations: Sex Workers $6,317
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Condoms: Policy, Tools, and Services $55,000